14 results about "Amikacin" patented technology

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine spray for treating rhinitis and a preparation method thereof.The traditional Chinese medicine spray is prepared from flos magnoliae liliflorae, fructus xanthii, herba ephedrae, fructus forsythiae, flos lonicerae, radix angelicae, herba asari, menthol, herba centipedae and herba menthae. Refining to obtain a fluid extract; and mixing the fluid extract with a penetration enhancer consisting of aminoketone and menthol, a sodium hyaluronate mucous membrane repairing agent, a pH regulator, an isoosmotic adjusting agent and a preservative to prepare spray liquid medicine, and finally performing sterile filtration and filling. Through efficient extraction and synergism of composite auxiliary materials, the permeability and bioavailability of the medicine are remarkably improved, and the symptoms such as nasal obstruction and running nose can be quickly relieved; meanwhile, the anti-inflammatory function and the function of actively repairing the damaged nasal mucosa are achieved, and the recurrence rate is reduced from the source; the pH and osmotic pressure of the preparation are precisely adjusted, the use is comfortable, and the quality is stable and controllable.

The application discloses an intelligent antibacterial hydrogel combined with a photosensitizer and an antibiotic as well as a preparation method and application thereof. The hydrogel takes oxidized dextran 40 as a hydrogel matrix, bonds 5-amino hexyl acetylpropionate into OAHAL through a Schiff base reaction, and is then crosslinked with amikacin to be prepared. The hydrogel has pH sensitivity, can effectively release drugs under an inflammatory slightly acidic environment, realizes on-demand release of the drugs, avoids overuse of the antibiotic, reduces toxic side effects, simultaneously loads two kinds of bactericidal drugs, 5-amino hexyl acetylpropionate and amikacin, and synergistically resists bacteria through two different mechanisms of photodynamic therapy and antibiotics, so that the antibacterial effect is significantly improved, and bacterial colonies caused by various types of wounds can be eliminated, and bacterial infection of a wound surface can be effectively prevented or treated.

The application discloses an N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and amikacin composition and application of the composition in treating chronic infection of drug-resistant bacteria. After the N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and the amikacin are combined, not only the sensitivity of pseudomonas aeruginosa to the amikacin can be obviously increased, but also the formation amount of the pseudomonas aeruginosa biofilm can be greatly reduced, so that the composition can be applied to preventing and treating chronic infection of drug-resistant pseudomonas aeruginosa.

The invention discloses application of amikacin in preparation of a medicine for treating melanoma, and relates to the technical field of biological medicine. The invention provides application of at least one of amikacin, pharmaceutically acceptable salts of amikacin, stereoisomers of amikacin, solvates of amikacin and polymorphic substances of amikacin in preparation of drugs for treating melanoma. In the invention, amikacin can inhibit proliferation, migration and invasion of melanoma cells; in a mouse transplantation tumor model, amikacin can also obviously delay tumor progression, and meanwhile obvious toxic reaction does not occur. Therefore, amikacin has the potential of serving as a new candidate drug for treating melanoma, can be used for treating melanoma, and provides a new research direction for reutilization of antibiotic drugs and treatment of melanoma.

Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

The application relates to the technical field of livestock reproduction, and particularly discloses a sperm microcapsule preparation and a preparation method; the sperm microcapsule preparation comprises a base liquid, carboxylated fullerene and sodium alginate; the base liquid comprises a sperm diluent, an amikacin mixed solution and egg yolk; the concentration of the carboxylated fullerene is 0-18 mu g / mL; and the concentration of the sodium alginate is 1%-2%. The application can reduce the damage of the microencapsulation process to sperm and improve the sperm quality in the sperm incubation process.

The application discloses a combined drug sensitivity test method for rapidly detecting the synergistic effect of amikacin and ceftazidime-avibactam, and the method comprises the following steps: uniformly coating a to-be-detected bacterial suspension on an MH agar plate, firstly pasting two ATM paper sheets and two CZA paper sheets respectively, and ensuring that the four paper sheets are uniformly distributed on the plate; secondly, pasting a to-be-detected ATM drug sensitivity paper sheet on a to-be-detected CZA paper sheet, and indicating the CZA ATM ; thirdly, pasting a to-be-detected CZA drug sensitivity paper sheet on a to-be-detected ATM paper sheet, and indicating the ATM CZA ; fourthly, respectively dropping 20 μL of sterile normal saline on the CZA ATM and ATM CZA ; and finally, placing the plate in a 35℃ incubator for 8 hours, measuring the diameters of the bacteriostatic rings of ATM, CZA, ATM CZA and CZA ATM , and determining the synergistic effect according to the diameters of the bacteriostatic rings and the drug sensitivity breakpoint standard. The application has the advantages of simple operation, rapidness, accuracy, low cost and the like.

The application provides a method for preparing a beta crystal form of amikacin, comprising the following steps: (1) dissolving an alpha crystal form of amikacin in anhydrous ethanol or a mixed solution of anhydrous ethanol and acetone, and obtaining a beta crystal form of amikacin wet product through recrystallization; and (2) drying the beta crystal form of amikacin wet product in a drying device with a relative humidity of 70% to 100% at 40 to 70 DEG C under normal pressure for 2 to 10 hours or under vacuum for 2 to 18 hours, so as to obtain a beta crystal form of amikacin with an ethanol content of less than 0.5% by weight. In the application, by controlling the humidity of the drying environment when the product is dried, the ethanol can be effectively removed while the moisture content of the amikacin wet product is maintained, so as to reduce the ethanol content of the amikacin product, meet the requirement of the ICH guideline Q3C that the ethanol content is not more than 0.5% by weight, and greatly improve the safety of amikacin clinical medication.

The application discloses a beta-lactamase and a gene for coding the beta-lactamase, and further discloses an expression cassette, a recombinant carrier, a recombinant cell or a recombinant bacteria, and a construction method of the recombinant bacteria, and further discloses the application of the beta-lactamase, the gene for coding the beta-lactamase, the expression cassette, the recombinant carrier, the recombinant cell or the recombinant bacteria, and the construction method of the recombinant bacteria in removing beta-lactam antibiotic pollution in the environment. The beta-lactamase gene is transformed into escherichia coli, so that the escherichia coli can hydrolyze beta-lactam antibiotics in the environment, including ampicillin, cefazolin, cefotaxime, imipenem and amikacin, and has great application value in eliminating beta-lactam antibiotic pollution in the environment.

The invention belongs to the technical field of membrane cleaning agents, and particularly relates to a membrane cleaning agent for removing microbial pollution as well as a preparation method and application of the membrane cleaning agent. The membrane cleaning agent comprises the following components: a stripping agent, a non-oxidized bactericide, a biological enzyme, an enzyme stabilizer, a bactericidal synergist and water, the stripping agent is an epoxy alkyl compound; the enzyme stabilizer is glycerol and / or propylene glycol; the bactericidal synergist is trimethoprem and / or diamethoprem, and the bactericidal synergist is trimethoprem and / or diamethoprem. The cleaning agent is characterized in that the stripping agent, the non-oxidation type bactericide, the biological enzyme, the enzyme stabilizer and the sterilization synergist are used as main components, the cleaning effect is synergistically improved from the two aspects of enhancing the stripping and elution effect and the sterilization effect of the cleaning agent, and microbial contamination on a membrane is efficiently removed; the membrane flux is greatly improved compared with that before cleaning, and the desalting performance is basically the same as that before cleaning.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

The present application belongs to the field of chemistry, and particularly relates to a three-dimensional gallium metal organic framework with fluorescence detection function and a synthesis and application method. A gallium metal organic framework compound with fluorescence recognition function has a chemical formula of {[(CH3)2(NH2)Ga(PPTA)]·0.5DMF} n . A preparation method of the gallium metal organic framework chemical substance is as follows: gallium nitrate, 4,4',4'',4'''-(4,4'-(1,4-phenylene)bis(pyridine-6,4,2-triyl))tetraanisic acid (PPTA) and oleic acid are added into a mixed solution of ethanol and N,N-dimethylformamide (DMF), stirred uniformly, and heated at constant temperature to obtain red block crystals, which are the gallium metal organic framework compound with fluorescence recognition function. The gallium metal organic framework compound is applied to detect aminoglycoside antibiotic amikacin. The fluorescence property is derived from ligand luminescence. The gallium metal organic framework material constructed shows different fluorescence properties from the ligand, can have specific fluorescence recognition function for amikacin, and has high sensitivity, anti-interference and recyclability.

The invention relates to the technical field of biomedicine, and provides application of combination of bacteriophage and antibiotic in preparation of a drug-resistant bacterial infection drug, the bacteriophage is acinetobacter baumannii or mycobacterium tuberculosis bacteriophage, and the antibiotic comprises one or more of amikacin, fosfomycin and polymyxin B. The invention provides the application of the combination of the bacteriophage and the antibiotic in the aspect of preparing the drug-resistant bacterial infection drug, the synergistic interaction can be realized, the drug resistance is reduced, the bacteriocidal spectrum is expanded, and the support is provided for the early intervention, accurate effect generation and prognosis improvement of the drug-resistant bacterial infection.